These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28236297)

  • 1. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
    Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
    Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
    Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
    Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
    Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
    Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
    JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R
    BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
    Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
    Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
    Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
    Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
    BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
    BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
    Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
    Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
    Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
    Michelsen TM; Dørum A; Tropé CG; Fosså SD; Dahl AA
    Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
    Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
    J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
    Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
    Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
    Michelsen TM; Dørum A; Dahl AA
    Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHAM-A Prospective Study of Weight and Body Composition After Risk-Reducing Bilateral Salpingo-oophorectomy.
    Price SAL; Finch S; Krejany E; Jiang H; Kale A; Domchek S; Wrede D; Wark JD; Hickey M
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e397-e405. PubMed ID: 37410931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.